Physician Spotlight
Hadi Yaziji, MD, FCAP, FASCP
Advancing Precision Medicine Through Breast Pathology, Biomarker Expertise, and Diagnostic Innovation
Professional Overview
A Physician Leader in Biomarker-Driven Pathology
Dr. Hadi Yaziji is a physician leader, breast pathologist, biomarker pathologist, and founder of NextGen Pathology. His career has focused on advancing diagnostic pathology, predictive biomarker testing, HER2 testing, immunohistochemistry, molecular diagnostics, and precision medicine. He is recognized for his expertise in breast pathology, biomarker pathology, cytopathology, surgical pathology, and molecular diagnostics.
As founder of NextGen Pathology, Dr. Yaziji brings together traditional diagnostic excellence with modern digital pathology infrastructure, supporting hospital partners, referring physicians, and healthcare organizations with subspecialty expertise and future-ready pathology workflows.
Areas of Expertise
Professional Leadership
Professional Leadership and Academic Contribution
Dr. Yaziji has served in professional leadership, academic, and educational roles across pathology and biomarker-focused medicine. He is associated with Vitro Molecular Laboratories and Pathology Learning Centers, has served as an Adjunct Clinical Professor affiliated with The University of Texas MD Anderson Cancer Center, and serves on the Board of Directors of the International Society of Applied Immunohistochemistry and Molecular Morphology.
Digital Pathology Strategy
Leading the Transition to Digital and AI-Ready Pathology
NextGen Pathology is investing in digital pathology infrastructure to support scalability, collaboration, subspecialty access, and AI-readiness. Dr. Yaziji's background in biomarker pathology, precision medicine, and diagnostic innovation helps guide NextGen's strategy as pathology continues to evolve from glass slides toward connected, digital, and data-enabled workflows.
Featured Publication
Research and Publication Focus
Dr. Yaziji's publication record has focused on HER2 testing, predictive tumor biomarkers, immunohistochemistry, and the diagnostic methods used to guide breast cancer treatment decisions. His recent work addresses the evolving role of HER2-low and HER2-ultralow assessment in the era of targeted therapy and precision medicine.
Recent Featured Publication
The Suitability of Repurposed, Legacy HER2 Immunohistochemistry Assays for the Detection of HER2 Low and Ultralow Expression: Current Limitations and Potential Considerations
Read PublicationHospital and Clinical Partner Value
Why This Matters to Our Partners
Hospitals and clinical partners working with NextGen Pathology gain access to physician leadership with deep experience in subspecialty pathology, breast diagnostics, predictive biomarkers, molecular diagnostics, digital pathology, and precision medicine. This expertise supports diagnostic confidence, clinical collaboration, and scalable pathology services for modern healthcare organizations.
Related Links